VR Logo

Pyxis Oncology Inc. (PYXS) download report


Healthcare | Biotechnology & Pharma Research

Pyxis Oncology Inc. (PYXS) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.

IPO Date: 08-Oct-2021

Co-Founder & Independent Chairman: Mr. John L. Flavin M.B.A., MBA, Ph.D.

CEO, Pres & Director: Dr. Lara S. Sullivan M.D., MBA

Listing: NASDAQ: PYXS

Country: United States

Headquarters: Cambridge, MA

Website: https://www.pyxisoncology.com

Key Facts

Market cap: $80.07 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-84.87 Mln

Cash: $247.09 Mln

Total Debt: $0.00 Mln

Insider's Holding: 18.77%

Liquidity: Low

52 Week range: $1.96 - 19.00

Shares outstanding: 32,817,100

Stock Performance

Time Period Pyxis Oncology (PYXS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-77.76-8.62-18.78
1 month-2.01-4.54-8.00
3 months-39.60-10.19-13.65
1 Year--1.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022